ABSTRACT
Cardiovascular diseases and diabetes
Advances in hypoglycaemic drugs, necessitates the adaptation of cardiac management regimens for the diabetic patient. The 2023 ESC guidelines summarise the results of recent clinical trials of GLP-1 receptor agonists and SGLT2 inhibitors in the context of preventing cardiovascular complications. The authors emphasise the need for screening both for diabetes in cardiac patients and for cardiovascular complications in patients with diabetes. In addition, a new SCORE2-Diabetes risk assessment scale was proposed for patients with type 2 diabetes aged 40-69 years without previously diagnosed atherosclerotic cardiovascular disease or the presence of severe target organ damage.
Piśmiennictwo
1. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44(39):4043-140
2. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148-58 [metaanaliza podsumowująca wyniki badań flozyn: EMPA-REG OUTCOME, DECLARE-TIMI 58, CREDENCE, VERTIS CV oraz dwa badania z programu CANVAS]
3. Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653-62 [metaanaliza podsumowująca wyniki badań dotyczących agonistów receptorów GLP-1: ELIXA, LEADER, SUSTAIN, EXSCEL, HARMONY Outcomes, REWIND, PIONEER 6 oraz AMPLITUDE-O]